Kapruvia (Difelikefalin)

Difelikefalin is a selective peripheral kappa‑opioid receptor agonist. By binding to these receptors on sensory nerves, it blocks the release of itch‑inducing neuropeptides and cytokines, thereby reducing the transmission of itch signals to the brain without producing central opioid effects.

The dose of Kapruvia is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response to therapy. Dosing recommendations are provided in the product’s prescribing information and should not be altered without medical guidance.

The safety of difelikefalin in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the decision to use it should involve a risk‑benefit assessment by the treating physician.

To request Kapruvia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Kapruvia’s mechanism—peripheral kappa‑opioid receptor activation—differs from antihistamines or topical agents, offering a targeted approach for CKD‑associated itch. Clinical studies have shown it can provide faster and more sustained itch relief compared with conventional therapies, especially in patients who do not respond to antihistamines.

Kapruvia must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product to maintain stability and potency.

Kapruvia is given as an intravenous injection. The infusion is administered by a qualified healthcare professional, typically during a hemodialysis session, following the dosing instructions provided in the prescribing information.

Serious risks include hypotension, severe hypersensitivity reactions such as anaphylaxis, and respiratory depression, particularly when used with other central nervous system depressants. Patients should be monitored closely for these events during and after infusion.

Kapruvia should be avoided in patients with known hypersensitivity to difelikefalin or any component of the formulation, and in those with unstable cardiovascular conditions where a drop in blood pressure could be hazardous. Clinicians should also exercise caution in patients receiving other opioid agonists or strong CNS depressants.